Microbial Biosynthesis of Benzylisoquinoline Alkaloids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of benzylisoquinoline alkaloids (BIAs) through traditional methods is costly, time-consuming, and generates toxic waste, with many structures being unattainable due to chiral centers and reactive functional groups, and rigorous extraction and purification procedures are required, limiting the availability of pharmacologically active intermediates.
Innovation Solution
Genetically engineered host cells, such as yeast, are used to express recombinant enzymes involved in the BIA biosynthetic pathway, allowing for the production of BIAs from simple precursor molecules or complex substrates, eliminating the need for harsh conditions and toxic waste, and enabling the production of pharmacologically active intermediates and derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional chemical synthesis methods are used to produce benzylisoquinoline alkaloids, then the production process can be established, but the process becomes costly, time-consuming, and generates toxic waste
Solution Approach 1:
The patent replaces traditional chemical synthesis methods with biological synthesis using genetically engineered microorganisms. The microbial cells express heterologous enzymes that catalyze the biosynthetic pathway from simple precursors to complex BIA molecules, substituting chemical reactions with enzymatic reactions that occur under mild physiological conditions, thereby eliminating harsh chemicals and toxic waste streams
Solution Approach 2:
The engineered microorganisms serve as self-contained biosynthetic factories that autonomously convert simple precursor molecules into complex BIA products through their metabolic pathways. The cells take up precursors from the medium, process them through multiple enzymatic steps, and excrete the final products, eliminating the need for manual intervention in each synthesis step and reducing harmful chemical byproducts
2Quantity of substance
If traditional extraction and purification procedures are used to isolate BIA intermediates from plants, then the compounds can be obtained, but the procedures are rigorous and time-consuming
Solution Approach 1:
The patent extracts the biosynthetic capability from plant sources and transfers it into microbial hosts through genetic engineering. Instead of extracting compounds from complex plant matrices requiring rigorous purification, the system produces BIA intermediates directly in microbial cells that can be easily harvested and processed, dramatically simplifying the isolation process
Solution Approach 2:
The patent uses microbial cells as intermediary factories that produce BIA intermediates in a controlled environment. These intermediates are secreted into the culture medium or can be easily accessed from the cells, serving as a convenient intermediary step between synthesis and final application, eliminating the need for complex plant extraction and purification procedures
3Productivity
If microbial biosynthesis is used to produce BIA intermediates, then the production can be achieved at low cost and high yields, but requires genetic engineering of host cells
Solution Approach 1:
The patent divides the complex BIA biosynthetic pathway into discrete enzymatic steps, each catalyzed by a specific heterologous enzyme. By expressing multiple genes encoding these enzymes in a coordinated manner within the microbial host, the system reconstructs the complete biosynthetic pathway modularly, achieving high productivity through systematic genetic engineering
Solution Approach 2:
The patent uses a universal microbial host platform (such as E. coli or yeast) that can be engineered to perform multiple functions: taking up various precursor molecules, processing them through the BIA biosynthetic pathway, and producing diverse BIA intermediates. This multi-functional system eliminates the need for separate production systems for each intermediate, reducing overall complexity while maintaining high productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables cost-effective, large-scale production of BIAs with high yields, avoiding extreme reaction conditions and toxic waste, and allows for the direct use of intermediates or modification for altered pharmacological activities, simplifying the extraction and purification processes.
Implementation Method 1
precursor molecules naturally produced in yeast, specifically L-tyrosine, are converted to various BIA intermediates in these engineered strains through a series of specific reactions catalyzed by recombinant enzymes
Data Source
AI summary
The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound. The invention also relates to methods of producing the benzylisoquinoline, as well as select precursors and intermediates thereof by culturing the host cells under culture conditions that promote expression of the enzymes that produce the benzylisoquinoline or precursors or intermediates thereof.